Efficacy Of Erythromycin Phonophoresis on Chronic Rhinosinusitis

Summary

The purpose of the study is to evaluate the therapeutic effect of erythromycin phonophoresis in reducing chronic rhinosinusitis.

Conditions

• Chronic Rhinosinusitis

Interventions

OTHER

Erythromycin Phonophoresis

The procedures of ultrasound phonophoresis will be as follows: Patients will be positioned comfortably, sitting in a relaxed position. The physiotherapist will explain the treatment procedures to the patient. The device cables will be checked before each session. The treatment will last 5 minutes for each maxillary sinus. The frequency will be set to 1 MHz, and the intensity will be 1 W/Cm2 for the maxillary sinuses. The ultrasound will be pulsed, and the treatment will consist of 12 sessions, 3 days per week.

DEVICE

Ultrasound (US)

Therapeutic US is produced by a transducer composed of a piezoelectric crystal, which converts electric energy into alternating compression and rarefaction of sound waves at a frequency greater than 20 kHz. The amplitude of the US wave is proportional to the displacement of the US transducer head during each half cycle. The amplitude represents the wave energy. The ultrasound waves penetrate the tissue on the way to the target organ and have two mechanisms of action (thermal and non-thermal), which may potentially work synergistically to reduce nasal symptoms (nasal blockage and secretions).

DRUG

Topical Erythromycin

Erythromycin is a 14-member macrolide originally discovered in the 1950s. It has broad-spectrum antimicrobial action, inhibiting bacterial protein synthesis. studies have shown that erythromycin has immunomodulatory and anti-inflammatory activity independent of its antimicrobial action Erythromycin is a broad-spectrum macrolide antibiotic, wherein its bactericidal effect occurs by the inhibition of protein synthesis. It is used for the treatment of infections affecting the skin and mucosa; it shows immunomodulatory characteristics

OTHER

Medical treatment

Saline nasal wash 3 times daily for a month.

Sponsors & Collaborators

• Cairo University

  lead OTHER

Principal Investigators

• Nahla Mahmoud Elkassas, B.Sc · Physotherapist at Alexanderia Police Hospital

• Hussein Gamal Hussein Mogahed, PhD · Assistant Professor, Cairo university

• Mustafa Mohamed Abdelnaby, PhD · Assistant Professor, Alexandria university

• Aya Gamal Fawzy Elsayed, PhD · Lecturer, Cairo university

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

25 Years

Max Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-07-07

Primary Completion

2025-09-07

Completion

2025-09-15

Countries

• Egypt

Study Locations